Every parliamentary written question tabled by Rachel Gilmour this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 61–69 of 69 · Department of Health and Social Care
If his Department will make an assessment of the adequacy of public funding for Devon Hospiccare in Exeter.
Palliative care services are included in the list of services that the integrated care boards (ICBs) in England, including the NHS Devon ICB, under which Devon Hospiscare falls, must commission. This promotes a more consistent national approach and suppor...
If he will make an assessment of the potential merits of further regulating social care micro-providers.
The Care Quality Commission (CQC) is the independent regulator of health and social care in England. The CQC has powers under the Health and Care Act 2008 to regulate adult social care services, to make sure they provide safe, effective, compassionate, an...
How many people have been reported missing from (a) hospitals and (b) other health care settings in each of the last four years for which data is available.
The following table shows a count of patient safety incidents, reported as occurring where the incident category is absconder or missing patient, broken down by care setting, each year from 2020/21 to 2023/24:Care setting of occurrence2020/212021/222022/2...
What plans his Department has for the role hospices will play in shifting care into the community.
We have committed to develop a 10-Year Health Plan to deliver an National Health Service fit for the future, by driving three shifts in the way health care is delivered. We will carefully be considering policies, including those that impact people with pa...
What steps his Department is taking to (a) increase funding for epilepsy research and (b) improve treatment options for patients with epilepsy.
The Department funds research into epilepsy via the National Institute for Health and Care Research (NIHR). The NIHR spent almost £19 million on 46 epilepsy research projects in the five years from April 2019 to March 2024. Additionally, over this period,...
Whether he plans to roll out NHS-funded Hybrid Close Loop technology to all Type 1 Diabetics in the UK.
In December 2023, the National Institute for Health and Care Excellence published the Technology Appraisal guidance, and recommended that the National Health Service in England makes Hybrid Closed Loop (HCL) systems available to eligible adults, and all c...
What assessment he has made of the potential impact of the introduction of the National Care Institute for Health and Care Excellence severity modifier in 2022 on the (a) appraisal of Enhertu for H
The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in its evaluations independently, and in consultation with stakeholders. The severity modifier that the NICE introduced in 2022 is...
If he will make representations to NICE on their decision to no longer offer Enertu for women suffering from metastatic HER2-LOW breast cancer.
Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. NICE’s methods are internationally respected, and have been developed through extensive work with industry, academics and the public to ensure they appropriately capture the costs and benefits, and best reflect social values. These are very difficult decisions to make, and it is important that they are made independently and based on the available evidence.We understand that despite NICE instigating an exceptional pause in the process to allow for commercial negotiations to take place with the companies, Daiichi Sankyo and AstraZeneca, a deal to enable patient access to this treatment on the NHS in England has not been reached.We know NICE’s announcement has come as a blow to many women and their families. We understand that NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu and have made it clear to the companies that their pricing of the drug remains the main obstacle to access.Within 16 weeks of the publication of final guidance, companies can also request a rapid review to consider new patient access scheme proposals, with the aim of establishing a pricing agreement that would improve cost-effectiveness and enable patient access to high-cost medicines. The Government wants to see a deal reached to make Enhertu available. NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.
Whether he plans to provide covid-19 vaccinations to the (a) families and (b) carers of patients with immunosuppressant diseases.
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact. The JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.